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Background: Rabies virus is the main etiologic agent of the widespread neurological disease rabies. Recently, the
China rabies virus vaccine strain CTN-1 adapted to chicken embryo cells, which has been designated as CTNCEC25,
was obtained and demonstrated to have high immunogenicity. However, the full genome sequence of CTNCEC25
and its phylogenetic relationship with other rabies virus street and vaccine strains have not been characterized.
Results: The complete genome of CTNCEC25 was sequenced and analyzed. The length of CTNCEC25 genome is
11,924 nucleotides (nt), comprising a 3′ leader sequence of 59 nt, nucleoprotein (N) gene of 1,425 nt, phosphoprotein
(P) gene of 989 nt, matrix protein (M) gene of 803 nt, glycoprotein (G) gene of 2,067 nt, RNA-dependent RNA polymerase
gene (L) of 6,474 nt and a 5′ trailer region of 71 nt. A comparison of the entire genomes of CTN-1 and CTNCEC25
identified 16 nt substitutions and 1 deletion, resulting in 8 amino acid (aa) changes in the five structural proteins
with one in L (aa 1602), two in M (aa 99 and 191) and six in mature G (aa 147, 333, 389, 421 and 485). The percentage
homology of the CTNCEC25 genomic sequence with other fully sequenced rabies virus strains ranged from 81.4% to
99.9%. Phylogenetic analysis indicated that CTNCEC25 was more closely related with those recently isolated China street
strains than other vaccine strains. Virus growth analysis showed that CTNCEC25 achieved high rate of propagation in
cultured cells.
Conclusions: In this study, the complete genome of CTNCEC25 was sequenced and characterized. Our results showed
that CTNCEC25 was more closely related to wild street strains circulating in China than other vaccine strains. Sequence
analysis showed that the G protein ectodomain amino acid sequence identity between CTNCEC25 and other rabies
virus strains was at least 90% identical. Furthermore, CTNCEC25 achieved high virus titers in cultured cells. Given that
CTNCEC25 has high immunogenicity and induced strong protective immune response in animals, these results
collectively demonstrated that CTNCEC25 is an ideal vaccine strain candidate for producing human vaccine with high
quality and safety in China.
Keywords: Genome sequence, Rabies virus, CTNCEC25, Chicken embryo cell, VaccineBackground
Rabies, which is an ancient global fatal central nervous
system (CNS) disease, affects almost all kinds of mam-
mals, including humans [1]. The mortality of rabies is
almost 100%, and it is estimated that more than 55,000
people die from rabies worldwide annually, with about* Correspondence: gcpzxy0402@aliyun.com
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unless otherwise stated.95% of those deaths occurring in the developing world
such as Asia and Africa (see WHO Fact Sheet No. 99).
China has the second highest incidence of rabies after
India, and a total number of 108,412 human rabies cases
were recorded in China during the 55-year period be-
tween 1950 and 2004 [2].
Rabies virus (RABV) is the main causative agent of
rabies and is the type species of the genus Lyssavirus of
the family Rhabdoviridae. RABV has a non-segmented,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mately 12 kb that encodes five structural proteins in the
order (3′ to 5′) of nucleoprotein (N), phosphoprotein (P),
matrix protein (M), glycoprotein (G) and RNA-dependent
RNA polymerase (large protein, L) [3,4]. The viral RNA
genome together with the N, P and L proteins forms a
helical ribonucleoprotein (RNP) that is packaged into a
bullet-shaped structure and wrapped by an envelope
comprising an inner layer of the M protein and the
transmembrane spike G protein [1]. While the RNP
complex is the entity responsible for viral transcription
and replication within the cytoplasm of the host cell,
the G and M proteins play pivotal roles in viral assem-
bly and budding [5,6].
The RABV G protein is the only viral protein exposed
on the surface of the virus. Previous studies have estab-
lished that G protein is not only the major determinant
of viral pathogenicity but is also the major protective
antigen that induces the production of virus-neutralizing
antibodies (VNAs) responsible for the immune re-
sponses of the host [7-10]. Moreover, the G protein is
also involved in the neurotropism of RABV [11-18]. A
number of antigenic sites to which neutralizing mono-
clonal antibodies bind were mapped in the G protein,
including antigenic site I (aa 231), II (aa 34 - 200), III (aa
330 - 357), IV (aa 264) and “a” (aa 342 - 343) [19]. In
addition, a linear epitope named G5 was also identified
in the G protein (aa 244 - 281) [20,21]. Among these
antigenic sites, aa 147 and 333 have been shown to be
critical for G protein function as mutation in either of
these two sites significantly affected RABV antigenicity
and pathogenicity [22,23]. Furthermore, a region be-
tween aa 164 to 303 of the Nishigahara strain G protein
also plays an important role in virus pathogenicity for
adult mice, with aa 242, 255 and 268 constituting the
key residues [24,25].
Currently, the pathogenesis of RABV has not been
fully elucidated and vaccination is the only effective
method to protect against RABV infection. Since the
first development of a rabies vaccine by Pasteur in the
late 19th century, vaccination has been widely used in
both domestic animals as well as reservoir species
[26,27]. At present, a number of RABV strains were used
for vaccine production in different countries. Four virus
strains, CTN-1, aG, PM and PV, have been applied in
human rabies vaccine production in China and CTN-1
and aG strains are Chinese domestic isolates [28]. The
CTN-1 strain was first isolated from brain tissue of a pa-
tient with rabies from Zibo, Shandong province while
the aG strain was obtained from a rabid dog in Beijing
[28]. However, although both the CTN-1 and aG strains
are indigenous to China, they have distinct phylogenetic
relationship. Previous studies suggested that the aG
strain was more closely related with strains in northernand northeast part of China and phylogenetic analysis
based on the N gene showed that the aG strain mainly
clustered with strains from Japan and America but dis-
tantly clustered with most China street strains while the
CTN-1 strain clustered preferentially with China native
street viruses [29,30], suggesting that the CTN-1 strain
had closer genetic relationship with street viruses pre-
vailing in China. It has been assumed that the efficiency
of cross protection against the epidemic street virus con-
ferred by rabies vaccine correlated with the homology
between the vaccine strain and the challenge strains
[31]. Therefore, the CTN-1 strain is theoretically more
suitable for vaccine production than the aG strain in
China.
Recently, a CTN-1 strain adapted to chicken embryo
cells (CECs), which has been named CTNCEC25, was
successfully obtained and demonstrated to have high im-
munogenicity and potency to induce a strong protective
immune response in animals [32]. Besides, CTNCEC25
lost pathogenicity to adult mice by intracerebral inocula-
tion [32]. In the present study, to gain more insight
into the biological characteristics of CTNCEC25, the
complete sequence of the CTNCEC25 strain was se-
quenced and characterized. Sequence comparison and
phylogenetic analysis demonstrated that CTNCEC25
was more closely related with those recently isolated
China RABV street strains than other vaccine strains
commonly used in China. Virus growth curve showed
that CTNCEC25 replicated stably and maintained high
titers at cultured cells. Therefore, these results demon-
strated the potential use of the CTNCEC25 strain for
producing human rabies vaccine in China.
Results
The genome organization of the CTNCEC25 strain
Based on the nucleotide sequence determined using a
total of 13 primer pairs (as shown in Table 1), the complete
sequence of the CTNCEC25 strain was obtained and sub-
mitted to the NCBI GenBank (GenBank accession no.
KJ466147). The genome length of CTNCEC25 was 11,924
nucleotides (nt) and the overall organization of the
CTNCEC25 strain was similar to that of the parental
CTN-1 strain except that it has one deletion in the poly
A tail of the P gene and is summarized as follows: a 3′
leader region of 59 nt (1 - 59), N gene (60 - 1,484), P gene
(1,487 - 2,475), M gene (2,481 - 3,283), G gene (3,289 -
5,355), L gene (5,380 - 11,853), and the 5′ trailer region of
71 nt (11854 - 11924). The coding sequence (CDS) of the
five structural proteins are located as follows: 1,353-nt N
protein (72 - 1,424), 894-nt P protein (1,516 - 2,409),
609-nt M protein (2,496 - 3,104), 1,575-nt G protein
(3,316 - 4,890) and 6,387-nt L protein (5,407 - 11,793).
The comparison of the complete CTNCEC25 genomic
sequence with those selected RABV strains available in
Table 1 Primers used in this study








































aPosition from the 5′ terminal region of the full-genome sequence of the
CTN-1 strain.
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similarity of the CTNCEC25 strain to other RABV
strains (Table 2). The results showed that the percentage
homology of the CTNCEC25 strain at nucleotide level
with other full-length genomes ranged from 81.5% with
SHBRV-18 strain to 99.9% with the parental CTN-1
strain, indicating high relatedness of the CTNCEC25
strain with other RABV strains (Table 3).
Sequence comparison of the genome of CTNCEC25
and CTN-1
To investigate in detail the sequence variation after the
adaption of CTN-1 to CECs, the genome sequence of
CTNCEC25 and the parental CTN-1 strain was com-
pared and analyzed (Table 4). Compared to that of
the CTN-1 strain, a total of 16 nucleotide substitutions
and 1 deletion, which resulted in 8 aa residues changes
in the five structural proteins, were identified in theCTNCEC25 strain. The G gene was the most varied
gene of the CTNCEC25 strain with 7 nucleotide muta-
tions. All the seven mutations except one in the G gene
non-coding region (5251 nt), were non-synonymous
which changed 5 aa residues in the G protein. In contrast,
although the L gene possessed 6 nucleotide mutations,
only one of them affected the amino acid sequence. In
addition, the N gene has 1 synonymous mutation and the
P gene has a deletion of one A nucleotide in the potential
polyadenylation signal. The M gene has 2 mutations which
affected 2 aa residues in M protein.
The finding that a deletion of one A nucleotide was
occurred in the gene junction of P and M was unex-
pected as several studies have shown that a 3’- U-U-U-
U-U-U-U-5’ (U7) tract at the end of each gene was
essential for the polyadenylated tail of the five struc-
tural protein genes and was well conserved in all these
five structural protein genes [3,33]. To further investigate
the heterogeneity of the gene junctions of P and M, the
CTNCEC25 P gene was used to searched against the nu-
cleotide sequences at the NCBI database and a total of 41
RABV strains with complete genome sequenced was se-
lected to compare the sequence heterogeneity of the P-M
gene junctions. The summary of the sequence analysis is
shown in Figure 1. The sequence across the P-M junction
was wild type (with U7 tract) in 34 of 41 genomes and
the shortening of U7 tract to U6 was found in three ge-
nomes including CTNCEC25. In the rest four genomes
that were not wild type, the U tract was extended to U8
in three and interrupted by a C residue (U5CU1) in one
genome (Figure 1). The above data showed that muta-
tions that are known to eliminate termination of tran-
scription might be selected and preserved in virus
population during evolution.
Structural features of the G protein of the CTNCEC25 strain
As the G protein is essential for viral pathogenicity,
the G protein amino acid sequence variation between
CTNCEC25 and CTN-1 was investigated. Compared
to the CTN-1 G protein, amino acids Lys147, Arg333,
Glu389, Pro421 and Ser485 were changed to Glu147,
Gln333, Lys389, Gln421 and Pro485, respectively, in the
CTNCEC25 G protein (Table 4). Among these amino
acids, Lys147 and Arg333 have been shown to be essential
for the pathogenesis of RABV [11,34-38]. The results
also imply that antigenicity would be affected in
CTNCEC25.
To investigate the G protein ectodomain sequence
identity of CTNCEC25 with other RABV street or vac-
cine strains, pairwise comparisons using the G protein
ectodomain amino acid sequence was performed. The
results showed that the identity of the G protein ectodo-
main sequence ranged from 90.0% to 99.1% between
CTNCEC25 with other RABV strains (Table 5).
Table 2 The RABV strains for which complete genome or the G gene sequence is available that were used in this study
Virus strain Accession no. Isolate country Length (bp)
Vaccine strains CTNCEC25 KJ466147 China 11,924
CTN-1 FJ959397 Zibo, China 11,925
SRV9 AF499686 China 11,928
SAG2 EF206719 France 11,928
ERA EF206707 Germany 11,931
SAD B19 M31046 America 11,928
HEP-Flury AB085828 America 11,615
FluryLEP DQ099524 Germany 11,711
PM1503 DQ099525 Germany 11,723
PV M13215 France 11,932
RV-97 EF542830 Russia 11,932
3aG G L04522 Beijing, China 1,575
Street strains HN10 EU643590 Hunan, China 11,923
BD06 EU549783 Hunan, China 11,924
DRV DQ875051 Jilin, China 11,863
MRV DQ875050 Henan, China 11,869
FJ008 FJ866835 Fujian, China 11,924
D01 FJ712193 Zhejiang, China 11,925
JX08-45 GU647092 China 11,922
DRV-AH08 HQ450385 Anhui, China 11,924
SHBRV 18 AY705373 America 11,923
8743THA EU293121 Thailand 11,923
NNV-RAB-H EF437215 India 11,928
Nishigahara AB044824 Japan 11,926
HM65 AY257980 Thailand 1,575
CHAND03 AY987478 India 1,592
MAL1-HM AF325487 Malaysia 2,091
BeijingHu1 G EU700029 Beijing, China 1,575
GuizhouA10(H) G EU267745 Guizhou, China 1,575
Hebei0(H) G EU267752 Hebei, China 1,575
HNDB28 G EU008927 Hunan, China 1,575
Hubei0703081 G EF643518 Hubei, China 2,064
WG430 G DQ849060 Hunan, China 1,575
WG432 G DQ849059 Hunan, China 1,575
Yunnan_MD06 G EU253477 Yunnan, China 1,575
Zhejiang Wz1(H) G EF556198 Zhejiang, China 2,067
FY1 G DQ849044 Anhui, China 1,575
Yue1 G DQ849070 Guangxi, China 1,575
Jiangsu Wx0(H) G EU267772 Jiangsu, China 1,575
NC G DQ849064 Jiangxi, China 1,575
CQ92 G DQ849072 Chongqing, China 1,575
Yunnan_Qj07 G EU275240 Yunnan, China 1,575
YunnanTc06 G EU275242 Yunnan, China 1,575
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Table 3 Comparison of genome sequence similarity
between CTNCEC25 and several RABV strains
Strains Similarity (%) Strains Similarity (%)
CTN-1 99.9 HN10 93.4
SRV9 84.4 BD06 88.1
SAG2 84.4 DRV 83.7
ERA 84.6 DRV-AH08 88.0
SAD B19 84.4 MRV 84.2
HEP-Flury 84.8 SHBRV18 81.5
FluryLEP 84.9 FJ008 88.2
PM1503 84.5 D01 88.2
PV 84.4 JX08-45 93.4
RV-97 83.8 8743THA 88.4
Nishigahara 83.7 NNV-RAB-H 84.8
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RABV street and vaccine strains
To further determine the phylogenetic relationship of
the CTNCEC25 strain with others RABV strains, espe-
cially those recently isolated from different regions in
China, two phylogenetic analyses were performed using
either the complete genome sequences (Figure 2) or theTable 4 Comparison of the sequence difference between
the genomes of the CTNCEC25 and CTN-1 strains
Genome locationα Protein position Nucleotide/amino
acid substitution
(CTN-1→ CTNCEC25)
461 N G→ A/-b
2476 P G→ -c/-
2792 M T→ G/Leu→ Arg
3068 M C→ T/Ser→ Leu
3812 G-147 A→ G/Lys→ Glu
4371 G-333 G→ A/Arg→ Gln
4538 G G→ A/Glu→ Lys
4635 G C→ A /Pro→ Gln
4636 A→ G
4826 G T→ C/Ser→ Pro
5251 G C→ A/-
6289 L A→ G/-
7078 L G→ A/-
7750 L G→ A/-
9886 L G→ T/-
10141 L A→ G/-
10212 L G→ A/Arg→ Lys
αPosition from the 5′ terminal region of the full-genome sequence of the
CTN-1 strain.
bAmino acid synonymous mutation.
cNucleotide deletion.mature G protein amino acid sequences (Figure 3) of the
CTNCEC25 strain and others RABV strains, mainly
those recently isolated street strains circulating in China.
As expected, at the genomic level, the CTNCEC25
strain was most closely related with the parental CTN-1
strain (Figure 2 and 3), which was consistent with gen-
ome comparison analysis (Table 3). Furthermore, com-
pared to other vaccine strains used in China, such as
PM and PV, the CTNCEC25 strain was more closely re-
lated with those RABV street strains. This phenomenon
was even more pronounced when the phylogenetic tree
was built based on the mature G protein amino acid se-
quences, in which the CTNCEC25 strain was clustered
together with almost all of the selected recently isolated
China RABV street strains while other commonly used
vaccine strains were clustered into another group to-
gether with only a few China RABV street strains
(Figure 3). Therefore, the above results suggested
that the CTNCEC25 strain was phylogenetically more
closely related with those native China RABV street
isolates than other vaccine strains commonly used in
China.
Virus replication in cell culture
To compare the infectivities of the CTN-1 and
CTNCEC25 strains in both neuronal NA cells and the
nonneuronal Vero or CECs, viral replication was exam-
ined by analysis of progeny virus production in NA,
Vero or CECs infected with CTN-1 or CTNCEC25 at a
multiplicity of infection (MOI) of 3 fluorescent focus
units (FFUs)/cell. As illustrated in Figure 4A and B,
the viral titers of the CTNCEC25 strain in both NA
and Vero cells were comparable to that of the parental
CTN-1 strain and similar growth kinetics were observed
for these two viruses with peak titers at 72 hours post in-
fection (h p.i.) reaching about 108.0 FFUs/ml. As ex-
pected, CTNCEC25 replicated at a similar robustness
and reached high titers in CECs, although the titers were
slightly lower than that in NA or Vero cells (Figure 4C).
On the other hand, as the CTN-1 strain was previously
maintained in Vero cells, it replicated poorly in CECs
and the titers at 72 and 96 h p.i. were approximately 100-
fold lower than that of the CEC-adapted CTNCEC25
strain (Figure 4C). Therefore, the results indicated that
the adaptation of CTNCEC25 to CECs did not affect
virus replication in cultured cells.
Discussion
In the present study, the complete genome of the RABV
strain CTNCEC25, the first CTN-1 strain adapted to
CECs, was sequenced and analyzed. The results demon-
strated that the CTNCEC25 strain was closely related
to China RABV street strains recently isolated from dif-
ferent regions. Furthermore, although the CTNCEC25
Figure 1 Analysis of sequence across the gene junctions of P and M genes. (A) Sequence analysis of the PCR product of the P and M gene
junction in CTNCEC25. (B) Intergenic junction sequences of the P and M genes in 41 RABV genomes.
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and CECs (Figure 4), it caused no lethality in adult mice
by intracerebral inoculation [32], thus providing a ra-
tionale for its potential use for human vaccine produc-
tion in China.
Comparison of the nucleotide sequences of CTNCEC25
with CTN-1 identified that all nucleotide changes oc-
curred in the structural protein genes, with the G gene
being the most variable. Similar results were observed in
another attenuated RABV strain, RC-HL, which was de-
rived from the RABV Nishigahara strain after 330 pas-
sages in chicken embryos and cell cultures [24]. It has
been shown that the G gene was the most variable when
comparing the complete genome sequences of the RC-HLTable 5 Homologies of the ectodomain amino acid
sequences of the CTNCEC25 G protein with those of
other virus strains
Strain Identity (%) Strain Identity (%)
CTN-1 99.1 SHBRV 18 90.9
SRV9 93.8 BeijingHu1 95.9
SAG2 94.5 GuizhouA10(H) 94.1
ERA 94.8 Hebei0(H) 94.8
SAD B19 94.5 HNDB28 95.9
HEP-Flury 95.2 Hubei0703081 95.7
FluryLEP 94.8 WG430 95.7
PM1503 93.8 WG432 95.7
PV 94.8 Yunan_MD06 95.2
3aG 93.6 Zhejiang Wz1(H) 95.7
HN10 97.9 FY1 95.4
BD06 95.2 Yue1 95.4
DRV 90.0 Jiangsu Wx0(H) 94.5
MRV 93.2 NC 95.9
FJ008 95.4 CQ92 97.0
D01 95.4 Yunan_Qj07 95.2
JX08-45 96.6 YunnanTc06 95.7
RV-97 92.5 MAL1-HM 96.1
Nishigahara 94.1 CHAND03 94.5
8743THA 95.2 NNV-RAB-H 96.1strain and the Nishigahara strain [39]. Given that RABV is
highly neurotropic in nature and the fact the G protein is
the major structural protein involved in the neurotropism
of RABV by recognizing receptors on neurons, it is there-
fore not unexpected that the G protein underwent greater
selection pressure during adaptation to cultured nonneur-
onal cells.
Previous studies have identified several amino acids in
G protein that were important for the antigenicity and
pathogenicity of RABV [22,23]. In the present study, two
of these critical amino acids, aa 147 and 333, were found
to be mutated in CTNCEC25 G protein during adapta-
tion to CECs. Therefore, it was assumed that the patho-
genicity of CTNCEC25 may be severely attenuated in
adult mice, which was consistent with our previous
in vivo study showing that CTNCEC25 was apathogenic
to adult mice by intracerebral inoculation [32].
Sequence analysis identified that the Lyssavirus gen-
ome contains the signals essential for the transcription
initiation, termination and processing for all the five
structural protein genes, and the RABV is no exception
[4]. A consensus sequence, 3’-A/U-C-U-U-U-U-U-U-U-5’,
is conserved in all of the five RABV structural protein
genes [3]. Several studies using Vesicular stomatitis virus
(VSV), the prototype of the Vesiculovirus genus, showed
that the U7 tract is strictly conserved and essential for
VSV mRNA termination and polyadenylation, and either
shortening or interrupting it with a heterologous nucleo-
tide eliminates mRNA termination and polyadenylation
[40,41]. As is the case for CTNCEC25, however, the U7
tract is only conserved in four of the five structural protein
genes, N, M, G and L, but not the P gene, in which the U7
tract was shortened to U6. Therefore, it is assumed that
the expression of M gene, which is located downstream of
the P gene, would be affected in CTNCEC25 due to the
read-through of the upper P gene. Previous studies have
revealed that the M gene encodes a multifunctional pro-
tein that plays essential roles not only in mediating viral
assembly and budding but also in regulating the balance
between the transcription and replication of RABV. So
the disruption of M gene expression should certainly
impair the CTNCEC25 replication in cultured cells.
Although we did not perform transcriptional analysis
Figure 2 Phylogenetic analysis of the complete genome sequence of CTNCEC25 compared with other RABV strains. The tree was
constructed using the Neighbor-Joining algorithm in MEGA 4.0 software. The numbers below the branches are bootstrap values for 1000 replicates.
CTNCEC25 was marked with a black star.
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ruled out as the growth kinetics of CTNCEC25 in cul-
tured cells were indistinguishable from that of CTN-1
(Figure 4).
After careful inspection of the database, we found that
while the typical U7 tract was the preponderant se-
quence at the P-M junction, several types of disruption
of the typical U7 tract were observed, although with a
low frequency, in the P-M junctions, including shorten-
ing or lengthening of U7 tract to U6 or U8 and interrup-
tion of the U7 tract by a different nucleotide (Figure 1).
Therefore, it is possible that the RABV street strains
have accumulated mutations during evolution and main-
tained these mutations to increase their population
diversity, better adapt to their hosts or disseminate
infection to a new host species. On the other hand, it also
cannot rule out the possibility that different mechanisms
may exist upon the molecular biology between RABVand VSV, as RABV and VSV share distinct natural histor-
ies and pathogenicity despite the close relationship
within each other [4]. Further studies are needed to un-
ravel the mechanisms underlining the regulation of gene
expression of CTNCEC25.
Phylogenetic analysis using the genome sequence or
the mature G protein amino acid sequence identified
that CTNCEC25 shared high homology with wild strains
isolated from different regions in China. It has been pre-
viously reported that the identity of the ectodomain
amino acid sequence of RABV G protein directly corre-
lated with the efficacy of vaccination and VNAs displayed
cross-protection only when the amino acid sequence of
the G protein ectodomain was at least 74% identical [31].
The recent antigenic analysis using serological assay data
has also demonstrated that a 4.8% change in the G pro-
tein ectodomain amino acid sequence would cause a
change of one antigenic unit between viruses (equivalent
Figure 3 Phylogenetic analysis of the mature G protein amino acid sequences of CTNCEC25 compared with other RABV strains. The
tree was constructed using the Neighbor-Joining algorithm in MEGA 4.0 software. The numbers below the branches are bootstrap values for
1000 replicates. CTNCEC25 was marked with a black star.
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Figure 4 Growth curve analysis of the CTNCEC25 and CTN-1 strains in Vero (A), NA (B) or CECs (C). Cells were infected with indicated
virus at an MOI of 3 FFUs/cell. At different times p.i., the virus in the supernatant was harvested and titrated in BSR cells. Each data point was
determined from the average for three independent infections. Error bars represent standard deviations.
Zhu et al. Virology Journal 2014, 11:176 Page 9 of 12
http://www.virologyj.com/content/11/1/176to a two-fold change in antibody titer) and there is a gen-
erally good correlation between genetic distance in the G
protein and antigenic distance [42]. Therefore, it is rea-
sonable that the best vaccine strain should be the one
most closely related to the street strains circulating
within the target area. Sequence analysis showed that
compared to aG, PM and PV vaccine strains, which were
widely used in China for human vaccine production, the
CTNCEC25 strain was more closely related to RABV
strains circulated in China while the other three vaccine
strains were predominantly clustered with RABV strains
derived from other countries. In addition, the ectodomain
amino acid homology of the G proteins of CTNCEC25
with other RABV strains ranged from 90.0% to 99.1%
(Table 5), which significantly ranked above the threshold
74% for the presence of cross-protection. Taken together,
the above results indicated that CTNCEC25 was an ideal
candidate for human vaccine production in China.
The human rabies vaccines can be produced either
from animal tissues or cultured cells, such as CECs,
BHK or Vero cells [43]. The development of modern in-
dustrial cell cultivation and fermentation techniques
have greatly promoted the capacity of producing vac-
cines with high quantity and quality. Given the consider-
ation of purity and concentration of vaccines, vaccines
using cultured cells have quickly outdated the use of
tissue-derived rabies vaccines. However, although cell
culture vaccines are highly efficacious and immunogenic,these cell lines may have differences in genotypes or
phenotypes from the original cell line and thus may con-
tain oncogenic properties [44,45]. Therefore, great cau-
tion should be taken in using such cell lines for vaccine
manufacturing. Specific guidelines for producing human
vaccines using the continuous cell lines were enacted in
China and no more than 100 pg of host cellular DNA
per dose was allowed for authorized vaccine production
using Vero cell line according to the standard of the
Pharmacopoeia of the People's Republic of China (2010),
Volume III. On the other hand, CECs, which have lim-
ited life span than continuous cell lines, maintain the
normal cellular karyotype and thus guarantee no con-
tamination of foreign and oncogenic particles and are
expected to be a promising substitute substrate for pro-
duction of safe human vaccine [43]. The FluryLEP strain
has already been adapted to CECs to produce purified
chicken embryo cells vaccines, and has been recom-
mended by WHO and widely used in many countries
due to its high safety and efficacy, low cost and relative
simple manufacturing techniques [46-49]. Current vac-
cine production in China was almost exclusively based
on Vero cells, making vaccine strains adapted to CECs
urgently needed.
Conclusion
In this study, an CECs-adapted RABV strain CTNCEC25
was sequenced and characterized. Phylogenetic analysis
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RABV street strains circulating in China than other
RABV vaccine strains currently used in China. Sequence
comparison showed that the G protein ectodomain
amino acid sequence identity between CTNCEC25 and
other RABV strains was at least 90% identical. Further-
more, CTNCEC25 produced high virus titers in primary
culture cells while it lacked the pathogenicity for adult
mice. Collectively, these results demonstrated that the
CTNCEC25 strain is an ideal vaccine strain candidate




The CTN-1 strain (after 5 passages in Vero cell lines)
was obtained from National Institute for the Control of
Pharmaceutical and Biological Products (NICPBP). The
CTNCEC25 strain was prepared by adapting the CTN-1
strain to CECs through serial passage in CECs [32], and
passage 36 of the CTNCEC25 strain in CECs was
used in this study unless otherwise specified. BSR
cells (cloned from BHK-21), CECs and Vero cells were
maintained in M199 (Invitrogen) supplemented with
10% fetal bovine serum (FBS). Mouse neuroblastoma
NA cells were grown in Eagle’s minimal essential medium
supplemented with 10% FBS. All cells were incubated at
37°C in 5% CO2.
Primer design
According to the conserved regions of the genome se-
quence of the CTN-1 strain published in GenBank
(GenBank accession no. FJ959397), 13 pairs of primers
were designed to amplify the regions of CTNCEC25
strain using DNASTAR 7.0 software (DNASTAR Inc.,
Madison, WI, USA) and synthesized and purified using
PAGE purification by Invitrogen (Table 1).
RNA extraction, reverse transcription-PCR and direct
sequencing
Total RNA was extracted from supernatants of CTNCEC25
infected CECs using the QIAampViral RNA Mini Kit
(Qiagen) according to manufacturer’s instructions. The
first strand of cDNA was synthesized using the First
Strand cDNA Synthesis Kit (TOYOBO) and the cDNA
was amplified using the Platinum Taq DNA HIF I Poly-
merase (Invitrogen), according to the manufacturer’s
protocols. Then, the full-length cDNA was subjected to
nucleotide sequencing straightly by BGI-Beijing (Beijing,
China) and Invitrogen Life Technologies Corporation
(Shanghai, China) using the Chain Termination Method.
The nucleotide sequence of the full-length genome of
CTNCEC25 was submitted to GenBank under accession
no. KJ466147.Sequence alignment and phylogenetic analysis
The nucleotide sequences obtained were edited manually
using the DNASTAR 7.0. Multiple sequence alignments
were constructed using Clustal X [50] with default set-
tings. Phylogenetic trees were constructed on the basis
of multiple alignments using the neighbor-joining algo-
rithm in the software package MEGA 4. The reliability
of the phylogeny groupings was evaluated using boot-
strapping with 1000 replicates. The RABV strains with
complete genome or the G gene sequence available in
the GenBank used in this study were listed in Table 2.
Virus titration
The virus titer was determined using a modified rapid
fluorescence focus inhibition test as previously described
[51] and expressed in FFUs/ml. Briefly, a monolayer of
BSR cells in 96-well plates was incubated with serial
three-fold virus dilutions. At 24 h p.i., the cells were
fixed with 80% ice-cold acetone and stained with a
FITC-labeled monoclonal antibody against nucleoprotein
(Millipore) for 1 h at 37°C. The plates were examined by
fluorescence microscopy, and the number of fluorescent
foci presented in the wells was recorded. Endpoints were
defined as the highest dilutions with fluorescent foci less
than 30, and virus titers were calculated by the following
formula: virus titer (FFU/ml) = (the mean foci number in
the endpoint wells × 5 + the mean foci number in the wells
with lower dilutions next to the endpoint well) ÷ 2 × the
dilution factor of the lower dilutions × 20.
Virus growth analysis in cultured cells
NA, Vero and CEC cells (1 × 106) were infected with the
indicated viruses at an MOI of 3 FFUs/ml for single-step
growth analysis as previously described [39]. Briefly, after
1 h of incubation at 37°C, the inoculum was removed and
cells were washed three times with Hanks’ balanced salt
solution, then 3 ml of the corresponding fresh medium
was added to the cells. Cells were incubated at 37°C in 5%
CO2 and supernatants were harvested at the indicated time
points. Titration of viral stocks was performed by an direct
immunofluorescence assay as described above.
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